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SUMMARY
Following a period characterized by severe epidemics of sleeping sickness, restoration of eﬀective control and surveillance
systems has raised the question of eliminating the disease from sub-Saharan Africa. Given suﬃcient political and ﬁnancial
support, elimination is now considered a reasonable aim in countries reporting zero or less than 100 cases per year. This
success may lead health authorities across the aﬀected region to downgrade the disease from ‘neglected’ to simply being
ignored. In view of the signiﬁcant levels of under-reporting of sleeping sickness mortality in rural communities, this could
be a short-sighted policy. Loss of capacity to deal with new epidemics, which can arise as a consequence of loss of
commitment or civil upheaval, would have serious consequences. The present period should be seen as a clear opportunity
for public-private partnerships to develop simpler and more cost-eﬀective tools and strategies for sustainable sleeping
sickness control and surveillance, including diagnostics, treatment and vector control.
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IMPACT OF SLEEPING SICKNESS
A colonial disease or the colonial disease?
The starting point for sleeping sickness control is
inextricably linked to the incursion of the European
powers into sub-Saharan Africa in the 19th century.
Colonists hoping to proﬁt from Africa’s abundance
of raw materials and cheap or even ‘free’ (i.e. slave)
labour were disturbed to discover towards the end
of that century that the workforce was succumbing
in unprecedented numbers to a mysterious illness.
The disease was also perceived to be spreading across
the continent from the French, Portuguese and
Belgian territorial interests in West and Central
Africa towards the British and German colonies in
East Africa. A ﬂurry of scientiﬁc activity quickly
identiﬁed trypanosomes as the causative organisms
and that they were being transmitted exclusively by
tsetse ﬂies (for a detailed account of this brilliant, yet
often acrimonious, period in parasitological research
see the Reports of the Sleeping Sickness Commission
of the Royal Society, for example, Bruce et al. 1903).
There is no doubt that ‘the colonial disease’
(Lyons, 1992) was responsible, in the absence of host
immunity and eﬀective drugs, for hundreds of thou-
sands of deaths in the colonial period. We are now
aware that, even with the advantage of more eﬀective
diagnostics, data concerning sleeping sickness deaths
are subject to gross errors due to under-reporting
(Odiit et al. 2005). With hindsight it is reasonable to
infer that millions died from sleeping sickness during
the colonial period; to get some idea of the serious-
ness of the situation facing the colonial authorities,
this pandemic could be compared to the current
HIV/AIDS situation in Africa (Maudlin, 2006).
To further complicate control initiatives, it soon
became apparent that sleeping sickness was not a
single entity. The human disease inWest andCentral
Africa, referred to as Gambian sleeping sickness and
caused by Trypanosoma brucei gambiense, is chronic
in form. Because of the chronic nature of this disease
and the inaccessibility of the endemic regions it has
been diﬃcult to determine how long a patient may
have been infected with T. brucei gambiense ; recent
studies have estimated that, on average, it is usually
fatal within three years in the absence of treatment
(Checchi et al. 2008a). Rhodesian sleeping sickness,
the human disease in East and southern Africa
caused by Trypanosoma brucei rhodesiense is usually
fatal within 6–8 months of infection in the absence
of treatment (Odiit et al. 1997; Fe`vre et al. 2004).
Rhodesian sleeping sickness, if left untreated, is al-
ways fatal in humans but there have always been
suggestions that self-resolving and asymptomatic
chronic infections of Gambian sleeping sickness may
occur but it is accepted that even if they do exist they
will be few in number (Checchi et al. 2008b) or
misdiagnosed due to transient infections with other
trypanosome subspecies (Deborggraeve et al. 2008).
Critically, diagnosis and treatment of the two forms
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of sleeping sickness require diﬀering approaches
(Chappuis et al. 2005; Barrett et al. 2007).
The burden of sleeping sickness
As a result of intensive eﬀorts to control the disease
by colonial regimes using a variety of methods, there
was a steady decline in the number of reported cases
of sleeping sickness across Africa from the 1930s
onwards. However, the post-independence period of
the 1960s saw interest in, and funding for, control
programmes within the endemic countries falter, re-
sulting in a steep rise in incidence for the following
thirty years. As surveillance and health care pro-
grammes in the aﬀected regions were slowly restored
following this period of neglect there has been, from
1997 onwards, a decline in reporting of new cases
(Simarro et al. 2008). WHO (World Health Organ-
ization) has listed 36 countries endemic for sleeping
sickness, of which 24 are aﬀected by T. b. gambiense ;
seven countries (Angola, Democratic Republic of
the Congo, Sudan, Chad, Central African Republic,
Congo and Uganda) represent 98% of all reported
Gambian sleeping sickness cases. Thirteen countries
are endemic for Rhodesian sleeping sickness with
Uganda andTanzania accounting formost new cases.
1.35 million DALYs are lost due to sleeping sick-
ness; mortality related to sleeping sickness is ranked
ninth out of 25 among the human infectious and
parasitic diseases in Africa (Fe`vre et al. 2008a).
However, in considering these data, it must be borne
in mind that under-reporting is a major problem in
estimating the burden of sleeping sickness. This is
illustrated by the study of an outbreak of Rhodesian
sleeping sickness inUganda, which alarmingly found
that 92% of sleeping sickness deaths are never re-
ported (Odiit et al. 2005). This, despite the fact that
drugs to treat sleeping sickness are provided free of
charge by WHO thanks to a public-private partner-
ship with Sanoﬁ-Aventis. Treatment costs are high
because of the supplementary drugs involved and
the need for long hospitalization. It costs around
US$150 per patient (including drugs and hospitali-
zation) to treat a Rhodesian sleeping sickness case in
Uganda (Fe`vre et al. 2008b) – this may be compared
with the US$18 available per capita for healthcare in
Uganda (World Bank, 2006). The costs for treating
Gambian sleeping sickness are similarly relatively
high; for example a study of an outbreak in Demo-
cratic Republic of Congo (DRC) found sleeping
sickness-related costs were equivalent to 5 months’
income for aﬀectedhouseholds (Lutumba et al. 2007).
We may conclude that the burden sleeping sickness
imposes on rural settings is much greater than might
be expected from its relative incidence.
From primacy to neglect
From being ‘the Colonial disease’ (Lyons, 1992) at
the beginning of the 20th century, sleeping sickness
is now relegated to membership of a group deﬁned
as the ‘neglected tropical diseases ’ (NTDs), which
includes leprosy, schistosomiasis, onchocerciasis,
soil-transmitted helminths, lymphatic ﬁlariasis, dra-
cunculiais, dengue, cholera, trachoma, leishmaniasis,
Chagas disease and Buruli ulcer. NTDs aﬀect several
hundred million people but because they attract little
attention from donors, policymakers or public health
oﬃcials they are designated ‘neglected’ (Molyneux
et al. 2005). It has been suggested that this neglect
results largely from over-reliance on DALY esti-
mates in policy planning. For most sub-Saharan
African countries, accurate measurements of mor-
bidity and mortality from neglected tropical diseases
are diﬃcult to obtain and disease burden is inevitably
underestimated (King and Bertino, 2008). This in-
sight is pertinent when considering resources for
sleeping sickness which, as we have seen, is subject to
gross under-reporting (Fe`vre et al. 2008b) so that its
true burden may not be reﬂected in current estimates
(WHO Weekly Epidemiological Record at http://
www.who.int/wer/2006/wer8108/en/index.html).
CONTROLLING SLEEPING SICKNESS
Reservoirs of disease
Existence of a reservoir of a disease is conﬁrmed
when an infection within the target population can-
not be sustained after all transmission between target
and non-target populations has been eliminated
(Haydon et al. 2002). The persistence of infection in a
reservoir can be determined by longitudinal studies
and, in the case of Rhodesian sleeping sickness, such
studies were carried out exhaustively. In the Tinde
experiment in Tanzania (Ashcroft, 1959), T. b. rho-
desiense isolated from humans were serially trans-
mitted by tsetse through sheep for over 20 years and
remained human-infective. That wild animals could
be the reservoir of Rhodesian sleeping sickness
was established by injecting blood from an infected
bushbuck into a human volunteer (Heisch et al.
1958). Human volunteers were later used to dem-
onstrate that domestic animals, in this case cattle,
could also act as reservoirs of Rhodesian sleeping
sickness (Onyango and de Raadt, 1966). The relative
epidemiological signiﬁcance of wild/domestic animal
reservoirs for persistence of Rhodesian sleeping
sickness was not resolved until recently, when a
molecular marker (SRA gene) was used to distin-
guish non-human infective T. b. brucei from human
infective T. b. rhodesiense in livestock (Welburn et al.
2001a). Studies using this marker have demon-
strated the overwhelming importance of the dom-
estic animal reservoir for transmission of Rhodesian
sleeping sickness in present day Uganda, with up to
40% of cattle carrying human infective trypanosomes
in some endemic areas (Fe`vre et al. 2001).
There have been no longitudinal studies reported
forT. b. gambiense but, given the long-term nature of
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this form of disease, such experiments were probably
simply considered impractical. There is evidence
from studies in West Africa using PCR diagnostics
that T. b. gambiense is present in both domestic and
wild animals (Njiokou et al. 2006; Simo et al. 2006).
However, in the absence of experiments that show
T. b. gambiense is persistent in animals and animal-
to-human transmission, an animal reservoir for
Gambian sleeping sickness cannot and perhaps need
not be factored into the epidemiology of this form of
the disease (Welburn et al. 2001b). This diﬀerence in
primary reservoir of disease has always, consciously
or unconsciously, dictated diﬀerences in approach to
controlling the two forms of sleeping sickness.
Controlling Rhodesian sleeping sickness
In controlling Rhodesian sleeping sickness, the im-
portance of the animal reservoir was recognised by
Bruce from the start of his studies in Uganda (Bruce
et al. 1903). Armed with this knowledge it was but a
short step for colonial regimes to advocate the de-
struction of wildlife and habitat that supported
wildlife to control outbreaks of disease in East Africa.
While this approach may have seemed logical, the
ecological consequences of these methods were not
thought through. The ecology of much of this region
has changed considerably since colonial times and
wildlife populations aremuch reduced in comparison
with cattle forming the major reservoir of Rhodesian
sleeping sickness in present-dayUganda. This change
in the perception of the epidemiology of the disease
has had considerable impact on control strategies.
Modelling control options (whether to target the
animal reservoir, humans or vector) has shown that,
given the signiﬁcance of the animal reservoir, vector
control is by far the most eﬃcient method for
bringing outbreaks of Rhodesian sleeping sickness
under control (Welburn et al. 2001b).
If we assume that vector control is the desired
control option, this inevitably leads to a highly con-
tentious issue – how best to control the ﬂy? The
technical choices are simply laid out: (1) if insecti-
cides are the chosen route, synthetic pyrethroids
are now accepted as the insecticide of choice (Allsopp
and Hursey, 2004) (2) if a non-insecticide approach
is chosen then the alternatives are (a) baits (traps,
targets etc. with or without attractants and live baits,)
or (b) the sterile insect technique (SIT). There the
simplicity of tsetse control ends and more complex
economic and socio-economic factors must be
weighed. If the situation has already reached epi-
demic proportions then choices are stark and all
options are open to use; in the most recent epidemic
of Rhodesian sleeping sickness in Uganda in the
1980s–1990s, the whole gamut of vector control
methods were deployed including aerial and ground
spraying of insecticides, trapping involving local
communities and insecticide treated cattle (Lancien,
1991; Okoth et al. 1991; Okoth, 1999). Alongside
these tsetse measures, the human reservoir was dealt
with by treating those infected and attempts were
made to reduce the reservoir in cattle by chemo-
therapy. Taken together, these methods brought the
epidemic under control though the relative eﬃcacy of
these disparate approaches is not open to analysis
given the security situation in the country at that time
(Welburn et al. 2006). In such a serious situation,
where thousands of people are infected and millions
are at risk, it is understandable that every measure
available is thrown at the problem. In a sense, the
epidemic situation is the easier to deal with, as eco-
nomics must take a back seat in such circumstances.
This is in stark contrast to the endemic situation
when, with low levels of mortality, health economists
must weigh sleeping sickness control costs against
the many other demands on their budgets and par-
ticularly the pressure to devote available resources to
the ‘big three’ (HIV, TB and malaria), the tempta-
tion being to ignore NTDs (Molyneux, 2008). We
have seen in the 20th century that the results of this
neglect can be disastrous, sowing the seeds for further
epidemics sooner or later. One solution would be to
remove the vector altogether which could eliminate
Rhodesian sleeping sickness. The PanAfricanTsetse
and Trypanosomosis Eradication Campaign (PAT-
TEC) (http://www.who.int/trypanosomiasis_african/
partners/pattec/en/index.html) aims to eliminate
tsetse and trypanosomiasis from Africa altogether.
Isolated tsetse populations have been eliminated on
Unguja Island, Zanzibar using SIT (Vreysen et al.
2000) and the Okavango Delta in Botswana by aerial
spraying (Kgori et al. 2006). These approaches were
not aimed at sleeping sickness but rather to remove
tsetse as a threat to livestock with the economic ad-
vantages that could accrue. However, if the target
tsetse population is not isolated then re-invasion
makes elimination unlikely which in turn raises
awkward economic and social questions (Hargrove,
2003; Enserink, 2007).
Controlling Gambian sleeping sickness
While removing the vector that transmits Rhodesian
sleeping sickness is seen as a practical proposition
on the back of programmes to control animal reser-
voir, the ancient foci of Gambian sleeping sickness
are largely concentrated in the humid zones of
west and central Africa, not suitable for the rearing
of cattle and not targeted by trypanosomiasis control
programmes. Modelling diﬀerent control strategies
showed that early case detection and treatment
is most eﬀective against Gambian infections when
the involvement of an animal reservoir in the
epidemiology of this form of the disease remains
unresolved (Welburn et al. 2001b). The fact that in
practice active case ﬁnding has proven eﬀective over
many decades in controlling this form of the disease
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indicates that humans are the primary reservoir of
T. b. gambiense (Jannin and Cattand, 2004).
There are logistical problems with active case
ﬁnding in remote rural areas where health systems
are weak and attendance rates at screening are often
low. This approach to control relies on early diag-
nosis and appropriate chemotherapy, which both
pose problems due to the poor sensitivity and spe-
ciﬁcity of available parasitological and serological
tools but also due to the dangerous and cumbersome
drugs available for treatment.
Diagnosis is reliant ﬁrstly on serological screening
of the population at risk, usually by means of a Card
Agglutination Test for Trypanosomiasis (CATT).
Before treatment can commence clinicians would
normally require parasitological conﬁrmation of
the CATT-positive test as recommended by WHO
(1998); this usually involves simple microscopy or,
where available, more sophisticated techniques such
as the mini-anion exchange centrifugation method
(Lutumba et al. 2006). Treatment of serologically
positive individuals without parasitological conﬁr-
mation remains controversial yet failure to respond
to a CATT-positive test may have serious epidemi-
ological consequences (Simarro et al. 1999). Staging
sleeping sickness is mandatory to determine the
choice of drug therapy and at present staging re-
quires lumbar puncture to examine cerebrospinal
ﬂuid for parasites or, if parasites are not detected,
CSF white blood cell count (WHO, 1998).
Chemotherapy for ﬁrst (haemo-lymphatic) stage
of Gambian sleeping sickness is straightforward
involving a single drug, pentamidine. Treatment of
the second stage, when parasites invade the central
nervous system, is a much more fraught process
and still largely relies on the use of melarsoprol,
which is followed by a severe post-treatment re-
active encephalopathy in 10% of cases, of which
half die (Kennedy, 2006). Eﬂornithine (DFMO), a
novel alternative to melarsoprol treatment (only for
Gambian sleeping sickness), is safer to use (Burri and
Brun, 2003; Chappuis et al. 2005) but has the major
disadvantage that administration is labour intensive,
requiring intravenous infusion every six hours for
14 days (56 infusions in total), a real problem for
rural clinics (Priotto et al. 2008).
ENDEMICITY AND CONTROL
In countries reporting zero or less than 100 cases
of sleeping sickness per year, elimination1 is now
thought to be feasible given suﬃcient political and
ﬁnancial support (Simarro et al. 2008). While ac-
knowledging the success that active surveillance
measures have had from 1997 to 2006 in reducing the
number of new cases of Gambian sleeping sickness in
some settings, it is important to recognise that this
may lead health authorities to downgrade the disease
in their list of priorities. Such complacency has in the
past led to a loss of capacity to deal with the disease
when new epidemics arise. Theremust be continuing
concerns about the eﬀects which civil upheaval can
have on apparently stable endemic foci (Kaba et al.
2006; Berrang Ford, 2007; Courtin et al. 2008). The
important issue, as we enter a period of endemicity
for sleeping sickness is : how can the ‘punishment of
success’ (Simarro et al. loc.cit.) be best avoided?
In endemic areas, sleeping sickness cases occupy
more patient admission time than all other infectious
diseases excepting malaria yet their treatment has
been shown to be highly cost-eﬀective. Far from
being subject to neglect, increasing coverage of
therapy and reducing under-reporting of both forms
of sleeping sickness should instead be a priority for
health authorities (Fe`vre et al. 2008a). Lutumba et al.
(2007) suggest that because sleeping sickness has
such a serious economic impact on households while
controlling the disease is highly cost-eﬀective, health
oﬃcials should take into account the impact of sleep-
ing sickness on families in rural Africa, rather than
deferring to global statistics for disease burden
(published inWHOWeekly Epidemiological Record
at http://www.who.int/).
Diagnostics and chemotherapy
In the case of Gambian sleeping sickness the priority
is to develop new diagnostic and chemotherapeutic
tools to ease the ﬁscal burden of surveillance on the
aﬀected countries and hence promote and facilitate
its sustainability by integrating sleeping sickness
control into the normal activities of the available
health systems in transmission areas. Progress is
being made in detecting trypanosomes in blood and
cerebro-spinal ﬂuid based on a variety of techniques
including oligochomatography (Deborggraeve et al.
2006) and isothermal tests (Njiru et al. 2008) – the
ﬁrst steps towards a simpliﬁed molecular test. There
are also several promising developments in disease
biomarkers (Papadopoulos et al. 2004; Agranoﬀ et al.
2005). Blood or CSF markers for staging are in the
early stages of development (Lejon et al. 2002;
Courtioux et al. 2005) as are non-invasive diagnostic
tools (Lejon et al. 2006).
A major concern for the active case ﬁnding ap-
proach to controlling Gambian sleeping sickness is
the increasing number of treatment failures with
melarsoprol, reportedly as high as 30% in some foci
(Burri and Keiser, 2001; Stanghellini and Josenando,
2001; Robays et al. 2008). Unfortunately there are
1 Elimination is the reduction to zero of the incidence of a
disease in a deﬁned geographical area as a result of delib-
erate eﬀorts. Eradication is the permanent reduction to
zero of the worldwide incidence of infection as a result of
deliberate eﬀorts. Elimination demands continued eﬀorts
to prevent re-establishment while intervention is no longer
needed if eradication is achieved (Molyneux et al. 2004).
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no new drugs forthcoming for the treatment of late-
stage sleeping sickness (Croft, 2008) and focus has
been on trying to improve treatment regimes and
combination therapies using existing drugs. Combi-
nations of eﬂornithine, melarsoprol with nifurtimox
(used for treatment of Chagas’ disease) have been
trialled inUganda (Priotto et al. 2006) and the Congo
(Priotto et al. 2007) with encouraging results.
Vector control
If elimination of tsetse is unlikely to succeed on
ecological grounds or is considered too costly for the
endemic situation then alternative approaches for
controlling Rhodesian sleeping sickness must be
considered. We now have innovative tools to kill
tsetse ﬂies, which rely less on top-down interventions
but rather on the eﬀorts of the people at risk and
avoiding impositions on constrained local health
budgets. Long-lasting formulations of synthetic
pyrethroids that may be poured on or sprayed
on cattle (Thompson et al. 1991), while eﬀective at
killing tsetse proved too expensive for poor farmers
in Africa. However, it has recently been shown that it
is not necessary to treat the whole animal but only the
parts of cattle on which tsetse prefer to feed i.e. legs
and belly (Torr et al. 2007). This restricted appli-
cation technology (RAP) has reduced the cost of
treatment to around US 2 cents/animal/treatment
which has been shown to be aﬀordable and well
within the reach of poor farmers. Following this
breakthrough in the cost of treating livestock, a
public-private partnership has been formed – the
Stamp Out Sleeping Sickness campaign http://www.
sleepingsickness.org/) (Kabasa, 2007) – to promote
the use of RAP (for vector control and to protect
livestock from continued re-infection) combined
with trypanocidal drugs to improve herd health and
eliminate the animal reservoir of Rhodesian sleeping
sickness. This campaign is aimed primarily at halting
the northward spread of Rhodesian sleeping sickness
to prevent it coalescing with the focus of Gambian
sleeping sickness in the north west of Uganda
(Picozzi et al. 2005). This approach beneﬁts from
farmers’ natural desire to keep their herds healthy by
reducing the burden of trypanosomiasis and also
tick-borne diseases and the consequent control of
the reservoir of human disease may be viewed as a
very welcome public health bonus from a veterinary
intervention. That farmers are willing to pay for
this treatment promotes sustainability and avoids
the public goods issues (Milinski et al. 2002) associ-
ated with community based trapping programmes
(Brightwell et al. 2001).
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